Navigation Links
Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
Date:5/7/2009

WALTHAM, Mass., May 7 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that it will host a conference call and webcast on Thursday, May 14, 2009, at 4:30 p.m. EDT to review the Company's new business developments and first quarter financial results.

To access the live call, dial 877-397-0291 (domestic) or 719-325-4857 (international). The live webcast and replay access of the teleconference will be available on the Investors section of the Company's Website at http://www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI), is a genetics-focused personalized health company that develops preventative consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventative and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
2. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
3. T cell immunity enhanced by timing of interleukin-7 therapy
4. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
5. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
6. Interleukin-12 indicates survival prospects for melanoma patients
7. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
8. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
9. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
10. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
11. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... July 19, 2017 , ... USHEALTH Group, Inc. has ... in the prestigious CEO World Awards®. The coveted annual CEO World Awards ... services, CEO case studies, corporate social responsibility, and milestones from every major industry ...
(Date:7/17/2017)... ... July 17, 2017 , ... In a ... during Pregnancy , studies take a closer look at maternal depression, its effects ... with one study showing newer medications may be safer choices. , The scientific ...
(Date:7/17/2017)... (PRWEB) , ... July 17, 2017 , ... McGraw Family ... Patient Care and Train Next Generation of Healthcare Clinicians , NORWALK, Connecticut – ... is continuing its legacy of investing in community health by pledging up to $3 ...
(Date:7/17/2017)... ... July 17, 2017 , ... Altec Products, ... DocLink Advanced Admin Training in Atlanta, Georgia. The four-day training session, ... will allow them to manage DocLink more efficiently and effectively. , Covering topics ...
(Date:7/17/2017)... ... 17, 2017 , ... Western University of Health Sciences has ... Education for the sixth consecutive year, and also made the Honor Roll for ... Lebanon, Oregon, was recognized in seven categories: Collaborative Governance, Compensation & Benefits, Job ...
Breaking Medicine News(10 mins):
(Date:6/30/2017)... , June 30, 2017  AVACEN Medical (AVACEN) announced the ... The research describes the use of its AVACEN Treatment Method ... suffering from fibromyalgia. ... AVACEN Medical ... characterized by chronic widespread pain. It affects approximately 200 to 400 million ...
(Date:6/27/2017)... , June 27, 2017  Therapix Biosciences Ltd. (Nasdaq: ... company specializing in the development of cannabinoid-based drugs, today ... Market Opening Bell in New York, NY ... of its initial public offering (IPO) of American Depository ... March 2017. Dr. Elran Haber, Ph.D., Chief ...
(Date:6/20/2017)... and LAGUNA HILLS, Calif. ... presentation of new data that validate the use of ... stratify patients with multiple myeloma (MM). In a poster ... European Hematology Association (EHA) in Madrid, Spain ... of MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology: